Luminex Stock Forecast, Price & News

0.00 (0.00 %)
(As of 07/14/2021)
Today's Range
50-Day Range
52-Week Range
Average Volume873,093 shs
Market Capitalization$1.75 billion
P/E Ratio72.53
Dividend Yield1.08%
30 days | 90 days | 365 days | Advanced Chart
Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Luminex and its competitors with MarketBeat's FREE daily newsletter.

Luminex logo

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; and TDAS, an analysis program designed for development and optimization of nucleic acid assays. The company also provides xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism; ARIES system, a sample to answer real-time PCR platform; SYNCT data management software solutions; and ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 Assay, ARIES Flu A/B & RSV Assay, ARIES Group B Streptococcus Assay, ARIES Group A Strep Assay, ARIES Bordetella Assay, ARIES Norovirus Assay, ARIES C. difficile Assay, ARIES MRSA Assay, and SARS-CoV-2 Assay. In addition, it offers VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market; VERIGENE test cartridges; Amnis FlowSight imaging flow cytometers; Amnis ImageStream Mark II imaging flow cytometers; Amnis CellStream for cell and particle analysis; Guava easyCyte benchtop flow cytometers; Muse cell analyzers; and IDEAS, an image analysis software. Luminex Corporation was founded in 1995 and is based in Austin, Texas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.99 out of 5 stars

Medical Sector

285th out of 842 stocks

Surgical & Medical Instruments Industry

31st out of 74 stocks

Analyst Opinion: 1.0Community Rank: 3.7Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Luminex (NASDAQ:LMNX) Frequently Asked Questions

Is Luminex a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Luminex stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in LMNX, but not buy additional shares or sell existing shares.
View analyst ratings for Luminex
or view top-rated stocks.

What stocks does MarketBeat like better than Luminex?

Wall Street analysts have given Luminex a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Luminex wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Luminex's next earnings date?

Luminex is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Luminex

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) issued its quarterly earnings data on Wednesday, May, 5th. The medical instruments supplier reported $0.19 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.15 by $0.04. The medical instruments supplier had revenue of $110.69 million for the quarter, compared to analysts' expectations of $110.11 million. Luminex had a net margin of 5.39% and a trailing twelve-month return on equity of 4.66%.
View Luminex's earnings history

How has Luminex's stock price been impacted by COVID-19?

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LMNX shares have increased by 36.4% and is now trading at $36.99.
View which stocks have been most impacted by COVID-19

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex declared a quarterly dividend on Thursday, May 20th. Shareholders of record on Thursday, June 17th will be given a dividend of $0.10 per share on Thursday, July 8th. This represents a $0.40 annualized dividend and a yield of 1.08%. The ex-dividend date of this dividend is Wednesday, June 16th.
View Luminex's dividend history

Is Luminex a good dividend stock?

Luminex pays an annual dividend of $0.40 per share and currently has a dividend yield of 1.08%. Luminex does not yet have a strong track record of dividend growth. The dividend payout ratio of Luminex is 125.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, Luminex will have a dividend payout ratio of 33.33% next year. This indicates that Luminex will be able to sustain or increase its dividend.
View Luminex's dividend history.

What price target have analysts set for LMNX?

3 analysts have issued 12 month price targets for Luminex's shares. Their forecasts range from $37.00 to $37.00. On average, they anticipate Luminex's stock price to reach $37.00 in the next year. This suggests a possible upside of 0.0% from the stock's current price.
View analysts' price targets for Luminex
or view top-rated stocks among Wall Street analysts.

Who are Luminex's key executives?

Luminex's management team includes the following people:
  • Mr. Nachum Shamir, Chairman, CEO & Pres (Age 67, Pay $1.91M)
  • Mr. Harriss T. Currie, CFO, Sr. VP of Fin. & Treasurer (Age 59, Pay $824.12k)
  • Mr. Richard W. Rew II, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 53, Pay $693.94k)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 51, Pay $660.42k)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 59, Pay $633.57k)
  • Mrs. Kendel B. Martin CPA, VP of Accounting
  • Jeff Christensen, Sr. Director of Investor Relations
  • Mr. Eric S. Shapiro, Sr. VP of Global Marketing (Age 57)
  • Ms. Nancy M. Fairchild, Sr. VP of HR (Age 67)
  • Dr. Charles J. Collins, Sr. VP of R&D (Age 44)

What is Nachum “Homi” Shamir's approval rating as Luminex's CEO?

53 employees have rated Luminex CEO Nachum “Homi” Shamir on Nachum “Homi” Shamir has an approval rating of 87% among Luminex's employees.

Who are some of Luminex's key competitors?

What other stocks do shareholders of Luminex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include NVIDIA (NVDA), Baidu (BIDU), Cisco Systems (CSCO), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Square (SQ), Marvell Technology (MRVL), AbbVie (ABBV) and CRISPR Therapeutics (CRSP).

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Who are Luminex's major shareholders?

Luminex's stock is owned by a number of institutional and retail investors. Top institutional investors include Alliancebernstein L.P. (1.06%), State of Alaska Department of Revenue (0.06%), 6 Meridian (0.03%), Villere ST Denis J & Co. LLC (0.01%) and Veriti Management LLC (0.01%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Harriss T Currie, Nachum Shamir, Nancy Fairchild, Randall Myers, Richard W Rew II and Stephen L Eck.
View institutional ownership trends for Luminex

Which institutional investors are selling Luminex stock?

LMNX stock was sold by a variety of institutional investors in the last quarter, including Veriti Management LLC, and 6 Meridian. Company insiders that have sold Luminex company stock in the last year include Harriss T Currie, Nachum Shamir, and Richard W Rew II.
View insider buying and selling activity for Luminex
or view top insider-selling stocks.

Which institutional investors are buying Luminex stock?

LMNX stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Villere ST Denis J & Co. LLC, and State of Alaska Department of Revenue. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, Nachum Shamir, and Stephen L Eck.
View insider buying and selling activity for Luminex
or or view top insider-buying stocks.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $36.99.

How much money does Luminex make?

Luminex has a market capitalization of $1.75 billion and generates $417.40 million in revenue each year. The medical instruments supplier earns $15.17 million in net income (profit) each year or $0.32 on an earnings per share basis.

How many employees does Luminex have?

Luminex employs 1,325 workers across the globe.

What is Luminex's official website?

The official website for Luminex is

Where are Luminex's headquarters?

Luminex is headquartered at 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]

This page was last updated on 7/31/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.